Gt Biopharma, INC S-1 registration statements

GT Biopharma, Inc. has filed a registration statement for the resale of up to 9,723,057 shares of common stock by existing stockholders.

GT Biopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of 22.6 million shares of common stock by existing selling stockholders, while facing Nasdaq delisting risk and going concern doubts.

GT Biopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 14.59 million common shares by selling stockholders, stemming from recent private placements and advisory agreements.

GT Biopharma, a clinical-stage biopharmaceutical company, has filed an amended registration statement to allow selling stockholders to resell up to 54.4 million shares, including those from a recent private placement and a new $20 million committed equity facility, while disclosing a 'going concern' doubt and recent Nasdaq compliance regain.

GT Biopharma, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for the resale of up to 120.5 million shares by selling stockholders, while simultaneously addressing a Nasdaq listing compliance issue and disclosing substantial doubt about its ability to continue as a going concern.

GT Biopharma is launching a public offering of common stock and warrants to raise capital for the development of its TriKE and Dual Targeting TriKE immuno-oncology products.

GT Biopharma has filed an exhibit detailing the terms of common stock purchase warrants, outlining exercise conditions, adjustments, and transferability.

GT Biopharma is conducting a public offering of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

GT Biopharma has filed an amendment to its Form S-1 registration statement to register the resale of up to 740,000 shares of common stock issuable upon the exercise of warrants held by selling shareholders.

GT Biopharma is registering the resale of up to 740,000 shares of common stock issuable upon the exercise of warrants held by selling shareholders, with the company not receiving any proceeds from the resale.